News
Prescription Drug Freight Fraud, June 2026 report
March and April 2026 saw thousands of shipments of drugs imported into the US, including weight loss drugs and antibiotics. We studied these shipments to learn more about their manufacturers and contents.
[...]Fake medicines in Mexico, November 2025 – May 2026
Americans buying prescription medicines in Mexico are overlooking widespread drug counterfeiting in the country, and as AFPs popularize medical tourism to lower costs, what happens in Mexico’s drug supply chain is even more of a problem for Americans.
[...]June 1, 2026: Up to 18 years for counterfeit pill conspirators in Massachusetts
The scheme, which produced counterfeit oxycodone, Adderall, and Xanax, is linked to over a dozen deaths, according to prosecutors.
[...]May 26, 2026: Maryland PDAB passes a price cap on Ozempic, as Virginia’s governor questions board efficacy
Ozempic, the second drug that the state has set an upper payment limit on, will be capped at $274 for a 30-day supply.
[...]May 18, 2026: FDA warns 503B compounding pharmacy for producing tirzepatide after shortage ended
The ProRx warning letter signals increased FDA scrutiny of compounded weight loss product that are not intended to be compounded in the US.
[...]Safety risks in the GLP-1 market: an update on weight loss medication, May 2026
Criminal counterfeiters are exploiting Americans’ demand for blockbuster diabetes and weight loss drugs made with semaglutide and tirzepatide, while compounders, telehealth companies, and med spas strain and skirt public health measures to meet high demand.
[...]An Arkansas newspaper printed an ad hawking foreign drugs. Are foreign “pharmacies” advertising in your local newspaper?
An Arkansas newspaper printed an ad hawking foreign drugs. Are foreign “pharmacies” advertising in your local newspaper? On May 18, 2026, PSM sent a letter rebuking the Arkansas Democrat-Gazette for selling ad space to a Canadian online pharmacy last month. The advertisement, which promised to “save buyer’s up to 80% on their prescription drugs,” promotes…
[...]May 11, 2026: Connecticut AG’s crackdown leads to major platform halting sales of “research grade” weight loss chemicals to U.S.
In a major settlement, Made-in-China.com will stop selling research chemicals to U.S. buyers following an investigation by Connecticut’s Attorney General.
[...]May 4, 2026: FDA moves to restrict large-scale compounding of three weight loss drugs
The FDA proposed restricting three GLP-1 drugs from the 503B bulks list, which would prevent outsourcing facilities from compounding them from raw ingredients without a clear clinical need.
[...]Partnership for Safe Medicines Applauds FDA Action to Curb Unsafe Compounding of GLP-1 Medications
The Partnership for Safe Medicines strongly supports the Food and Drug Administration’s proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list. This action reflects sound science, sound law, and a clear-eyed commitment to patient safety. Full statement inside.
[...]